Air Lease Corporation Shares of Class A Common Stock Form of Underwriting Agreement
Exhibit 1.1
Air Lease Corporation
Shares of Class A Common Stock
Form of Underwriting Agreement
, 2011
X. X. Xxxxxx Securities LLC
Credit Suisse Securities (USA) LLC
As Representatives of the
several Underwriters listed
in Schedule 1 hereto
c/o X. X. Xxxxxx Securities LLC
000 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Credit Suisse Securities (USA) LLC
As Representatives of the
several Underwriters listed
in Schedule 1 hereto
c/o X. X. Xxxxxx Securities LLC
000 Xxxxxxx Xxxxxx
Xxx Xxxx, Xxx Xxxx 00000
Ladies and Gentlemen:
Air Lease Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to
the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting
as representatives (the “Representatives”), an aggregate of shares of Class A Common
Stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of
the Underwriters, up to an additional shares of Class A Common Stock of the Company (the
“Option Shares”). The Underwritten Shares and the Option Shares, including for the avoidance of
doubt, any such shares offered under the Directed Share Program (as defined in Section 2(e)), are
herein referred to as the “Shares”. The shares of Class A Common Stock and Class B Non-Voting
Common Stock, par value $0.01 per share, of the Company are referred to herein as the “Stock”.
The Company hereby confirms its agreement with the several Underwriters concerning the
purchase and sale of the Shares, as follows:
1. Registration Statement. The Company has prepared and filed with the Securities and
Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules
and regulations of the Commission thereunder (collectively, the “Securities Act”), a registration
statement (File No. 333-171734), including a prospectus, relating to the Shares. Such registration
statement, as amended at the time it became effective, including the information, if any, deemed
pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration
statement at the time of its effectiveness (“Rule 430 Information”), is referred to herein as the
“Registration Statement”. As used herein, the term “Preliminary Prospectus” means each prospectus
included in such registration statement (and any amendments thereto) before effectiveness that is
furnished by the Company to the Underwriters for distribution in connection with the offering of
the Shares, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities
Act and the prospectus included in the Registration Statement at the time of its effectiveness that
omits Rule 430 Information, and the term “Prospectus” means the prospectus in the form first used
(or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in
connection with confirmation of sales of the Shares. If the Company has filed an abbreviated
registration statement pursuant to Rule 462(b) under the Securities Act
(the “Rule 462 Registration Statement”), then any reference herein to the term “Registration
Statement”
shall be deemed to include such Rule 462 Registration Statement. Any reference in this
Agreement to the Registration Statement shall be deemed to refer to and include the exhibits
incorporated by reference therein. Capitalized terms used but not defined herein shall have the
meanings given to such terms in the Registration Statement and the Prospectus.
At or prior to the Applicable Time (as defined below), the Company had prepared the following
information (together with the pricing information set forth on Annex E, the “Pricing Disclosure
Package”): a Preliminary Prospectus dated , 2011 and each “free-writing
prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex E hereto.
“Applicable Time” means [A/P].M., New York City time, on , 2011.
2. Purchase of the Shares by the Underwriters.
(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters
as provided in this Agreement, and each Underwriter, on the basis of the representations,
warranties and agreements set forth herein and subject to the conditions set forth herein, agrees,
severally and not jointly, to purchase from the Company the respective number of Underwritten
Shares set forth opposite such Underwriter’s name in Schedule 1 hereto (or such number increased as
set forth in Section 10 hereof) at a price per share (the “Purchase Price”) of $ .
In addition, the Company agrees to issue and sell the Option Shares to the several
Underwriters as provided in this Agreement, and the Underwriters, on the basis of the
representations, warranties and agreements set forth herein and subject to the conditions set forth
herein, shall have the option to purchase, severally and not jointly, from the Company the Option
Shares at the Purchase Price less an amount per share equal to any dividends or distributions
declared by the Company and payable on the Underwritten Shares but not payable on the Option
Shares.
If any Option Shares are to be purchased by the Underwriters, the number of Option Shares to
be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to
the aggregate number of Option Shares being purchased as the number of Underwritten Shares set
forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set
forth in Section 10 hereof) bears to the aggregate number of Underwritten Shares being purchased
from the Company by the several Underwriters, subject, however, to such adjustments to eliminate
any fractional Shares as the Representatives in their sole discretion shall make.
The Underwriters may exercise the option to purchase Option Shares at any time in whole, or
from time to time in part, on or before the thirtieth day following the date of the Prospectus, by
written notice from the Representatives to the Company. Such notice shall set forth the aggregate
number of Option Shares as to which the option is being exercised and the date and time when the
Option Shares are to be delivered and paid for, which may be the same date and time as the Closing
Date (as hereinafter defined) but shall not be earlier than the Closing Date or later than the
tenth full business day (as hereinafter defined) after the date of such notice (unless such time
and date are postponed in accordance with the provisions of Section 10 hereof). Any such notice
shall be given at least two business days prior to the date and time of delivery specified therein;
provided, that if the same date and time as the Closing Date is specified therein, such
notice shall not be required to be given at least two business days prior to such date.
(b) The Company understands that the Underwriters intend to make a public offering of the
Shares as soon after the effectiveness of this Agreement as in the judgment of the Representatives
is advisable, and initially to offer the Shares on the terms set forth in the Prospectus. The
Company
-2-
acknowledges and agrees that the Underwriters may offer and sell Shares to or through any
affiliate of an Underwriter.
(c) Payment for the Shares shall be made by wire transfer in immediately available funds to
the account specified by the Company to the Representatives in the case of the Underwritten Shares,
at the offices of Xxxxx Xxxx & Xxxxxxxx LLP, 000 Xxxxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx at 10:00
A.M., New York City time, on 2011, or at such other time or place on the same
or such other date, not later than the fifth business day thereafter, as the Representatives and
the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the
time and place specified by the Representatives in the written notice of the Underwriters’ election
to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is
referred to herein as the “Closing Date”, and the time and date for such payment for the Option
Shares, if other than the Closing Date, is herein referred to as the “Additional Closing Date”.
Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as
the case may be, shall be made against delivery to the Representatives for the respective accounts
of the several Underwriters of the Shares to be purchased on the Closing Date or the Additional
Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of
such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities
of The Depository Trust Company (“DTC”) unless the Representatives shall otherwise instruct.
(d) The Company acknowledges and agrees that the Underwriters are acting solely in the
capacity of an arm’s length contractual counterparty to the Company with respect to the offering of
Shares contemplated hereby (including in connection with determining the terms of the offering) and
not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person.
Additionally, none of the Representatives nor any other Underwriter is advising the Company or any
other person as to any legal, tax, investment, accounting or regulatory matters in any
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be
responsible for making its own independent investigation and appraisal of the transactions
contemplated hereby, and the Underwriters shall have no responsibility or liability to the Company
with respect thereto. Any review by the Underwriters of the Company, the transactions contemplated
hereby or other matters relating to such transactions will be performed solely for the benefit of
the Underwriters and shall not be on behalf of the Company.
(e) It is understood that up to 1% of the Underwritten Shares offered (the “Directed Shares”)
will initially be reserved by the several Underwriters for offer and sale upon the terms and
conditions to be set forth in the most recent Preliminary Prospectus and in accordance with the
rules and regulations of the Financial Industry Regulatory Authority (“FINRA”) to officers and
employees of the Company and its subsidiaries and certain other persons associated with the Company
and its subsidiaries who have heretofore delivered to Barclays Capital Inc. offers to purchase
Underwritten Shares in form satisfactory to Barclays Capital Inc. (such program, the “Directed
Share Program”) and that any allocation of such Underwritten Shares among such persons will be made
in accordance with timely directions received by Barclays Capital Inc. from the Company;
provided, that under no circumstances will Barclays Capital Inc. or any Underwriter be
liable to the Company or to any such person for any action taken or omitted in good faith in
connection with such Directed Share Program. It is further understood that any Directed Shares not
affirmatively reconfirmed for purchase by any participant in the Directed Share Program by 9:00
A.M., New York City time, on the first business day following the date hereof or otherwise not
purchased by such persons will be offered by the Underwriters to the public upon the terms and
conditions set forth in the Prospectus.
-3-
3. Representations and Warranties of the Company. The Company represents and warrants
to each Underwriter that:
(a) Preliminary Prospectus. No order preventing or suspending the use of any
Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus
included in the Pricing Disclosure Package, at the time of filing thereof, complied in all
material respects with the applicable requirements of the Securities Act, and no Preliminary
Prospectus, at the time of filing thereof, contained any untrue statement of a material fact
or omitted to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; provided,
that the Company makes no representation and warranty with respect to any statements or
omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in any Preliminary Prospectus, it being understood and
agreed that the only such information furnished by any Underwriter consists of the
information described as such in Section 7(b) hereof.
(b) Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable
Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case
may be, will not, contain any untrue statement of a material fact or omit to state a
material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, that the Company
makes no representation and warranty with respect to any statements or omissions made in
reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in
such Pricing Disclosure Package, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in
Section 7(b) hereof.
(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the
Preliminary Prospectus and the Prospectus, the Company (including its agents and
representatives, other than the Underwriters in their capacity as such) has not prepared,
used, authorized, approved or referred to and will not prepare, use, authorize, approve or
refer to any “written communication” (as defined in Rule 405 under the Securities Act) that
constitutes an offer to sell or solicitation of an offer to buy the Shares (each such
communication by the Company or its agents and representatives (other than a communication
referred to in clause (i) below) an “Issuer Free Writing Prospectus”) other than (i) any
document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act
or Rule 134 under the Securities Act or (ii) the documents listed on Annex E hereto, each
electronic road show and any other written communications approved in writing in advance by
the Representatives, which approval shall not be unreasonably withheld. Each such Issuer
Free Writing Prospectus described in clause (ii) complied in all material respects with the
Securities Act, has been or will be (within the time period specified in Rule 433) filed in
accordance with the Securities Act (to the extent required thereby) and, when taken together
with the Preliminary Prospectus and all other such Issuer Free Writing Prospectuses
accompanying as of the Applicable Time, or delivered prior to delivery of, such Issuer Free
Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing
Date, as the case may be, will not, contain any untrue statement of a material fact or omit
to state a material fact necessary in order to make the statements therein, in the light of
the circumstances under which they were made, not misleading; provided, that the
Company makes no representation and warranty with respect to any statements or omissions
made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon
and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in such Issuer
Free Writing Prospectus or
-4-
Preliminary Prospectus, it being understood and agreed that the only such information
furnished by any Underwriter consists of the information described as such in Section 7(b)
hereof.
(d) Registration Statement and Prospectus. The Registration Statement has been
declared effective by the Commission. No order suspending the effectiveness of the
Registration Statement has been issued by the Commission, and no proceeding for that purpose
or pursuant to Section 8A of the Securities Act against the Company or related to the
offering of the Shares has been initiated or, to the knowledge of the Company, threatened by
the Commission; as of the applicable effective date of the Registration Statement and any
post-effective amendment thereto, the Registration Statement and any such post-effective
amendment complied and will comply in all material respects with the applicable requirements
of the Securities Act, and did not and will not contain any untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary in order to
make the statements therein not misleading; and as of the date of the Prospectus and any
amendment or supplement thereto and as of the Closing Date and as of the Additional Closing
Date, as the case may be, the Prospectus will not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading; provided,
that the Company makes no representation and warranty with respect to any statements or
omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement, the Prospectus, or any
amendment or supplement thereto, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in
Section 7(b) hereof.
(e) Financial Statements. The financial statements (together with the related notes
thereto) of the Company and its consolidated subsidiaries included in the Registration
Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects
with the applicable requirements of the Securities Act and present fairly in all material
respects the financial position of the Company and its consolidated subsidiaries as of the
date indicated and the results of their operations and the changes in their cash flows for
the period specified; such financial statements have been prepared in conformity with
generally accepted accounting principles in the United States (“GAAP”) applied on a
consistent basis throughout the period covered thereby, and any supporting schedules
included in the Registration Statement present fairly in all material respects the
information required to be stated therein; and the other financial information included in
the Registration Statement, the Pricing Disclosure Package and the Prospectus has been
derived from the accounting records of the Company and its consolidated subsidiaries and
presents fairly in all material respects the information shown thereby; and there are no
financial statements that are required by the Securities Act to be included in the
Registration Statement, the Pricing Disclosure Package or the Prospectus that are not
included as required.
(f) No Material Adverse Change. Since the date of the financial statements of the
Company included in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, (i) there has not been any material change in the capital stock (other than the
issuance of shares of Stock upon the exercise of stock options and warrants, or in
connection with the vesting of restricted stock units, described as outstanding in, and the
grant of options, restricted stock units and other awards under existing equity incentive
plans described in, the Registration Statement, the Pricing Disclosure Package and the
Prospectus), any material change in short-term debt or long-term debt of the Company or any
of its subsidiaries (other than as a result of the Company or any of its subsidiaries
entering into any debt arrangements in the ordinary course of
-5-
business), or any dividend or distribution of any kind declared, set aside for payment,
paid or made by the Company on any class of capital stock, or any material adverse change,
or any development involving a prospective material adverse change, in or affecting the
business, properties, management, financial position, stockholders’ equity, or results of
operations of the Company and its subsidiaries taken as a whole; (ii) neither the Company
nor any of its subsidiaries has entered into any transaction or agreement (whether or not in
the ordinary course of business) that is material to the Company and its subsidiaries taken
as a whole or incurred any liability or obligation, direct or contingent, that is material
to the Company and its subsidiaries taken as a whole, except as may be permitted under
clause (i) of this Section 3(f); and (iii) neither the Company nor any of its subsidiaries
has sustained any loss or interference with its business that is material to the Company and
its subsidiaries taken as a whole and that is either from fire, explosion, flood or other
calamity, whether or not covered by insurance, or from any labor disturbance or dispute or
any action, order or decree of any court or arbitrator or governmental or regulatory
authority; except in each case as otherwise disclosed in or contemplated by the Registration
Statement, the Pricing Disclosure Package and the Prospectus.
(g) Organization and Good Standing. The Company and each of its subsidiaries set forth
on Schedule 2 (the “Significant Subsidiaries”), which schedule includes the only
“significant subsidiaries” of the Company as that term is defined in Rule 1-02(w) of
Regulation S-X, have been duly organized and are validly existing and in good standing under
the laws of their respective jurisdictions of organization, are duly qualified to do
business, and are in good standing in each jurisdiction in which their respective ownership
or lease of property or the conduct of their respective businesses requires such
qualification, and have all corporate or limited liability company power and authority
necessary to own or hold their respective properties and to conduct the businesses in which
they are engaged, except where the failure to be so qualified or in good standing or have
such corporate or limited liability company power or authority would not, individually or in
the aggregate, reasonably be expected to (i) have a material adverse effect on the business,
properties, management, financial position, stockholders’ equity, results of operations or
prospects of the Company and its subsidiaries taken as a whole or (ii) prevent or materially
interfere with the performance by the Company of its obligations under this Agreement (a
“Material Adverse Effect”). The Company, as of the date hereof, does not own or control,
directly or indirectly, any corporation, association or other entity, and as of the Closing
Date, will not own or control, directly or indirectly, any corporation, association or other
entity, other than (i) the subsidiaries listed in Exhibit 21.1 to the Registration
Statement, (ii) such other subsidiaries as are not required to be listed in such Exhibit
21.1 which were formed for the purpose of acquiring, leasing or financing aircraft, or (iii)
such other subsidiaries which were formed following the effective date of the Registration
Statement for the purpose of acquiring, leasing or financing aircraft.
(h) Capitalization. The Company has an authorized equity capitalization as set forth
in the Registration Statement, the Pricing Disclosure Package and the Prospectus under the
heading “Capitalization”; all the outstanding shares of capital stock of the Company have
been duly and validly authorized and issued and are fully paid and non-assessable and are
not subject to any pre-emptive rights; except as expressly described in or contemplated by
the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no
outstanding rights (including, without limitation, pre-emptive rights), warrants or options
to acquire, or instruments convertible into or exchangeable for, any shares of capital stock
or other equity interest in the Company or any of its subsidiaries, or any contract,
commitment, or agreement of any kind relating to the issuance of any capital stock of the
Company or any such subsidiary, any such convertible or exchangeable securities or any such
rights, warrants or options; the terms of the capital stock of the Company conform in all
material respects to the description thereof contained
-6-
in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and
all the outstanding shares of capital stock or other equity interests of each Significant
Subsidiary owned, directly or indirectly, by the Company have been duly and validly
authorized and issued, are fully paid and non-assessable and, except as described in or
contemplated by the Registration Statement, the Pricing Disclosure Package and the
Prospectus, or except pursuant to the terms and conditions of any and all debt agreements to
which the Company or any such Significant Subsidiary is, as of the date hereof, a party or
which are entered into in the ordinary course in connection with the purchase or refinancing
of aircraft, are owned directly or indirectly by the Company, free and clear of any lien,
charge, encumbrance, security interest, restriction on voting or transfer or any other claim
of any third party.
(i) Stock Options. With respect to the stock options (the “Stock Options”) granted
pursuant to the stock-based compensation plans of the Company and its subsidiaries (the
“Company Stock Plans”), (i) each Stock Option intended to qualify as an “incentive stock
option” under Section 422 of the Code so qualifies in accordance with the terms of its
grant, and (ii) each grant of a Stock Option was duly authorized by all necessary corporate
action, including, as applicable, approval by the board of directors of the Company (or a
duly constituted and authorized committee thereof) and any required stockholder approval by
the necessary number of votes or written consents, and the award agreement governing such
grant (if any) was duly executed and delivered by each party thereto. The Company has not
knowingly granted, and there is no and has been no policy or practice of the Company of
granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with,
the release or other public announcement of material information regarding the Company or
its subsidiaries or their results of operations or prospects.
(j) Underwriting Agreement. This Agreement and the performance by the Company of its
obligations hereunder have been duly authorized, and this Agreement has been duly executed
and delivered by the Company.
(k) The Shares. The Shares to be issued and sold by the Company hereunder have been
duly authorized by the Company and, when issued and delivered and paid for as provided
herein, will have been validly issued, will be fully paid and non-assessable and will
conform in all material respects to the descriptions thereof in the Registration Statement,
the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not
subject to any preemptive rights.
(l) No Violation or Default. Neither (i) the Company nor any of its Significant
Subsidiaries is in violation of its respective charter or bylaws or similar organizational
documents; (ii) the Company nor any of its subsidiaries is in default, and no event has
occurred that, with notice or lapse of time or both, would constitute such a default, in the
due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement or other agreement or instrument to which the
Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any of the property or assets of the Company or any of its
subsidiaries is subject; or (iii) the Company nor any of its subsidiaries is in violation of
any law or statute or any judgment, order, rule or regulation of any court or arbitrator or
governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above,
for any such default or violation that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.
(m) No Conflicts. The execution, delivery and performance by the Company of this
Agreement, the issuance and sale of the Shares and the consummation by the Company of the
-7-
transactions contemplated by this Agreement will not (i) conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, or
result in the creation or imposition of any lien, charge or encumbrance upon any property or
assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument to which the Company or any of its
subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to
which any of the property or assets of the Company or any of its subsidiaries is subject,
(ii) result in any violation of the provisions of the charter or bylaws or similar
organizational documents of the Company or any of its Significant Subsidiaries or (iii)
result in the violation of any law or statute or any judgment, order, rule or regulation of
any court or arbitrator or governmental or regulatory authority applicable to the Company or
any of its subsidiaries, except, in the case of clauses (i) and (iii) above, for any such
conflict, breach, violation or default that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.
(n) No Consents Required. No consent, approval, authorization, order, license,
registration or qualification of or with any court or arbitrator or governmental or
regulatory authority is required for the execution, delivery and performance by the Company
of this Agreement, the issuance and sale of the Shares and the consummation by the Company
of the transactions contemplated by this Agreement, (i) except for the registration of the
Shares under the Securities Act which has been obtained, and (ii) except for such consents,
approvals, authorizations, orders and registrations or qualifications as may be required (A)
by FINRA, (B) under applicable state securities or blue sky or foreign securities or world
sky laws in connection with the purchase and distribution of the Shares by the Underwriters,
and (C) by the New York Stock Exchange (the “Exchange”) in connection with the listing of
the Shares on such securities exchange.
(o) Legal Proceedings. Except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, there are no legal, governmental or regulatory
investigations, actions, suits or proceedings pending to which the Company or any of its
subsidiaries is a party or to which any property of the Company or any of its subsidiaries
is subject that, individually or in the aggregate, if determined adversely to the Company or
any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to
the knowledge of the Company, no such investigations, actions, suits or proceedings are
threatened or contemplated by any governmental or regulatory authority or threatened by
others; and (i) there are no current or pending legal, governmental or regulatory actions,
suits or proceedings that are required under the Securities Act to be described in the
Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and (ii) there are no statutes, regulations or contracts or other documents that are
required under the Securities Act to be filed as exhibits to the Registration Statement or
described in the Registration Statement, the Pricing Disclosure Package or the Prospectus
that are not so filed as exhibits to the Registration Statement or described in the
Registration Statement, the Pricing Disclosure Package and the Prospectus.
(p) Independent Accountants. KPMG LLP, who have certified certain financial statements
of the Company and its subsidiaries, is an independent registered public accounting firm
with respect to the Company and its subsidiaries within the applicable rules and regulations
adopted by the Commission and the Public Company Accounting Oversight Board (United States)
and as required by the Securities Act.
(q) Title to Aircraft and Other Property. The Company or one of its direct or indirect
wholly owned subsidiaries has legal and valid title to all aircraft reflected as owned by
-8-
such person in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, with a review of the chain of title having been carried out and a receipt of a
warranty xxxx of sale having been received by or on behalf of such person in accordance with
customary and reasonable practice in the aircraft industry in the areas in which the Company
operates, and good title to all other material personal property reflected as assets owned
by such person in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, in each case free and clear of all liens, security interests, pledges, charges,
encumbrances, mortgages and defects, except such as are disclosed in or contemplated by the
Registration Statement, the Pricing Disclosure Package and the Prospectus, pursuant to the
terms and conditions of any and all debt agreements to which the Company or any of its
subsidiaries is a party, or as permitted under aircraft leases entered into in the ordinary
course to which the Company or any of its subsidiaries is a party; any real property or
personal property held under lease by the Company is held under a lease that is valid,
existing and enforceable by the Company, with such exceptions as are disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus or as would not
reasonably be expected to have a Material Adverse Effect, and the Company has not received
any written or, to the knowledge of the Company, other notice of any material claim of any
sort that has been asserted by anyone adverse to the rights of the Company under any such
lease.
(r) Title to Intellectual Property. Except as disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus and except in each case for any failure to
own or possess such rights or any such conflict as would not reasonably be expected to have
a Material Adverse Effect, the Company and its subsidiaries own or possess adequate rights
to use all patents, patent applications, trademarks, service marks, trade names, trademark
registrations, service xxxx registrations, copyrights, licenses and know-how (including
trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures) necessary for the conduct of their respective businesses
as currently conducted and as proposed to be conducted, and the conduct of their respective
businesses will not conflict in any respect with any such rights of others. The Company and
its subsidiaries have not received any written or, to the knowledge of the Company, other
notice of any claim of infringement, misappropriation or conflict with any such rights of
others in connection with its patents, patent rights, licenses, inventions, trademarks,
service marks, trade names, copyrights and know-how, which would reasonably be expected to
result in a Material Adverse Effect.
(s) No Undisclosed Relationships. No relationship, direct or indirect, exists between
or among the Company or any of its subsidiaries, on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on
the other, that is required by the Securities Act to be described in the Registration
Statement and the Prospectus and that is not so described in such documents and in the
Pricing Disclosure Package.
(t) Investment Company Act. The Company is not and, after giving effect to the
offering and sale of the Shares and the application of the proceeds thereof received by the
Company as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, will not be an “investment company” within the meaning of the Investment Company
Act of 1940, as amended, and the rules and regulations of the Commission thereunder
(collectively, the “Investment Company Act”).
(u) Taxes. Except where the failure to pay or file or where such deficiency, liability
or lien would not reasonably be expected to have a Material Adverse Effect, (i) the Company
and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax
returns required to be paid or filed through the date hereof (after considering any
applicable extension);
-9-
and (ii) except as otherwise disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, (A) there is no tax deficiency that has been, or
could reasonably be expected to be, asserted against the Company or any of its subsidiaries
or any of their respective properties or assets, (B) since the date of the most recent
audited financial statements, the Company and its subsidiaries have not incurred any
liability for taxes other than in the ordinary course of its business, and (C) there is no
tax lien, whether imposed by any federal, state, foreign or other taxing authority,
outstanding against the assets, properties or business of the Company or its subsidiaries,
except for a tax lien for any tax, assessment, governmental or other similar charge which is
not yet due and payable.
(v) Licenses and Permits. The Company and its subsidiaries possess all licenses,
certificates, permits and other authorizations issued by, and have made all declarations and
filings with, the appropriate federal, state, local or foreign governmental or regulatory
authorities that are necessary for the ownership or lease of their respective properties or
the conduct of their respective businesses as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, except where the failure to possess or make
the same would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect; and except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has
received written or, to the knowledge of the Company, other notice of any revocation or
modification of any such license, certificate, permit or authorization except such
revocation or modification as would not reasonably be expected to have a Material Adverse
Effect.
(w) No Labor Disputes. No labor disturbance by or dispute with employees of the
Company or any of its subsidiaries exists or, to the knowledge of the Company, is
contemplated or threatened; the Company is not aware of any existing or imminent labor
disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal
suppliers, contractors or customers, except as would not reasonably be expected to have a
Material Adverse Effect.
(x) Compliance with and Liability under Environmental Laws. Neither the Company nor
any of its subsidiaries is in violation of any statute, law (including common law) or any
rule, regulation, requirement, judgment, decree, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal, storage,
transportation, or release or threat of release of hazardous or toxic substances or relating
to the protection or restoration of the environment, human exposure to hazardous or toxic
substances, or natural resources (collectively, “Environmental Laws”), owns, leases or
operates any real property contaminated with any substance that is subject to any
Environmental Laws, is liable for any off-site disposal or contamination pursuant to any
Environmental Laws, or is subject to any administrative or judicial proceeding (or to the
Company’s knowledge, any threatened proceeding) relating to any Environmental Laws, which
violation, contamination, liability or proceeding would, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect, and to the Company’s or any
subsidiary’s knowledge, there is no pending investigation, which would reasonably be
expected to lead to such a liability or proceeding.
(y) Compliance with ERISA. Except in each case as would not reasonably be expected to
have a Material Adverse Effect, (i) each employee benefit plan, within the meaning of
Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”),
for which the Company or any member of its “Controlled Group” (defined as any organization
which is a member of a controlled group of corporations within the meaning of Section 414 of
the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each,
a “Plan”) has been maintained in compliance with its terms and the requirements
-10-
of any applicable statutes, orders, rules and regulations, including but not limited to
ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of
ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding
transactions effected pursuant to a statutory or administrative exemption; (iii) for each
Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of
ERISA, the minimum funding standard of Section 412 of the Code or Section 302 of ERISA, as
applicable, has been satisfied (without taking into account any waiver thereof or extension
of any amortization period) and is reasonably expected to be satisfied in the future
(without taking into account any waiver thereof or extension of any amortization period);
(iv) the fair market value of the assets of each Plan exceeds the present value of all
benefits accrued under such Plan (determined based on those assumptions used to fund such
Plan); (v) no “reportable event” (within the meaning of Section 4043(c) of ERISA) has
occurred or is reasonably expected to occur; (vi) neither the Company nor any member of the
Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV
of ERISA (other than contributions to the Plan or premiums to the PBGC, in the ordinary
course and without default) in respect of a Plan (including a “multiemployer plan”, within
the meaning of Section 4001(a)(3) of ERISA); and (vii) to the knowledge of the Company,
there is no pending audit or investigation by the Internal Revenue Service, the U.S.
Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental
agency or any foreign regulatory agency with respect to any Plan. A material increase in
the aggregate amount of contributions required to be made to all Plans by the Company or its
subsidiaries in the current fiscal year of the Company and its subsidiaries compared to the
amount of such contributions made in the Company and its subsidiaries’ most recently
completed fiscal year has not occurred, nor is reasonably likely to occur.
(z) Disclosure Controls. The Company and its subsidiaries maintain a system of
“disclosure controls and procedures,” as defined in Rule 13a-15(e) promulgated under the
Securities Exchange Act of 1934, as amended (together with the rules and regulations of the
Commission thereunder, the “Exchange Act”), that complies with the requirements of the
Exchange Act and that has been designed to ensure that information required to be disclosed
by the Company in reports that it will file or submit under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the Commission’s
rules and forms, including controls and procedures designed to ensure that such information
is accumulated and communicated to the Company’s management as appropriate to allow timely
decisions regarding required disclosure.
(aa) Accounting Controls. The Company and its subsidiaries maintain systems of
“internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange
Act) that comply in all material respects with the requirements of the Exchange Act and have
been designed by, or under the supervision of, their respective principal executive and
principal financial officers, or persons performing similar functions, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP, including, but not limited to, a
system of internal accounting controls sufficient to provide reasonable assurance that (i)
transactions are executed in accordance with management’s general or specific
authorizations; (ii) transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain accountability for assets;
(iii) access to assets is permitted only in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken with respect to any
differences. Except as disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the Company is not aware of any material weaknesses in the
Company’s internal controls over financial reporting, and since the date of the audited
financial statements
-11-
included in the Pricing Disclosure Package, to the knowledge of the Company, there has
been no change in the Company’s internal control over financial reporting that has
materially affected, or is reasonably likely to materially affect, the Company’s internal
control over financial reporting. The Company’s auditors and the Audit Committee of the
Board of Directors of the Company have been advised of: (i) all significant deficiencies
and material weaknesses, if any, in the design or operation of the system of internal
controls over financial reporting which are known to the Company’s management and which have
adversely affected or are reasonably likely to adversely affect the Company’s ability to
record, process, summarize and report financial information; and (ii) any fraud known to the
Company’s management, whether or not material, that involves management or other employees
who have a significant role in the Company’s internal controls over financial reporting.
(bb) Insurance. The Company and its subsidiaries have insurance covering their
respective properties, operations, personnel and businesses, which insurance is in amounts
and insures against such losses and risks as the Company reasonably believes are adequate to
protect the Company and its subsidiaries and their respective businesses taken as a whole;
and neither the Company nor any of its subsidiaries (i) has received written notice from any
insurer or agent of such insurer that capital improvements or other expenditures are
required or necessary to be made in order to continue such insurance or (ii) believes that
it will not be able to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from similar insurers as may be
necessary to continue its business, except in each case as would not reasonably be expected
to have a Material Adverse Effect.
(cc) No Unlawful Payments. Neither the Company nor any of its subsidiaries nor, to the
knowledge of the Company, any director, officer, agent, employee or other person authorized
to act on behalf of the Company or any of its subsidiaries has (i) used any corporate funds
for any unlawful contribution, gift, entertainment or other unlawful expense relating to
political activity; (ii) made any direct or indirect unlawful payment to any foreign or
domestic government official or employee from corporate funds; (iii) violated or is in
violation of any provision of the Foreign Corrupt Practices Act of 1977; or (iv) made any
bribe, unlawful rebate, payoff, influence payment, kickback or other unlawful payment.
(dd) Compliance with Money Laundering Laws. The operations of the Company and its
subsidiaries are and have been conducted at all times in material compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency (collectively, the
“Money Laundering Laws”) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of its
subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of
the Company, threatened.
(ee) Compliance with OFAC. None of the Company, any of its subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the Company
or any of its subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”); and the
Company will not, directly or indirectly, use the proceeds of the offering of the Shares
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary,
joint venture partner or other person or entity, for the purpose of financing the activities
of any person currently subject to any U.S. sanctions administered by OFAC.
-12-
(ff) No Restrictions on Subsidiaries. Except (i) pursuant to the terms and conditions
of any and all debt agreements to which the Company or any of its subsidiaries is, as of the
date hereof, a party or which are entered into in the ordinary course in connection with the
purchase or refinancing of aircraft or (ii) as disclosed in or contemplated by the
Registration Statement, the Pricing Disclosure Package and the Prospectus, no subsidiary of
the Company is currently prohibited, directly or indirectly, under any agreement or other
instrument to which it is a party or is subject, from paying any dividends to the Company,
from making any other distribution on such subsidiary’s capital stock, from repaying to the
Company any loans or advances to such subsidiary from the Company or from transferring any
of such subsidiary’s properties or assets to the Company or any other subsidiary of the
Company.
(gg) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to
any contract, agreement or understanding with any person (other than this Agreement) that
would give rise to a valid claim against the Company or any of its subsidiaries or any
Underwriter for a brokerage commission, finder’s fee or like payment in connection with the
offering and sale of the Shares.
(hh) No Registration Rights. No person has the right to require the Company or any of
its subsidiaries to register any securities for sale under the Securities Act by reason of
the filing of the Registration Statement with the Commission or the issuance and sale of the
Shares, except as disclosed in or contemplated by the Registration Statement, the Pricing
Disclosure Package and the Prospectus.
(ii) No Stabilization. The Company has not taken, directly or indirectly, any action
designed to or that would reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Shares.
(jj) Business with Cuba. The Company has complied with all provisions of Section
517.075, Florida Statutes (Chapter 92-198, Laws of Florida, as amended) relating to doing
business with the Government of Cuba or with any person or affiliate located in Cuba.
(kk) Forward-Looking Statements. No forward-looking statement (within the meaning of
Section 27A of the Securities Act and Section 21E of the Exchange Act) contained in the
Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or
reaffirmed without a reasonable basis or has been disclosed other than in good faith.
(ll) Statistical and Market Data. Nothing has come to the attention of the Company
that has caused the Company to believe that the statistical and market-related data included
in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not
based on or derived from sources that are reliable and accurate in all material respects.
(mm) Xxxxxxxx-Xxxxx Act. There is and has been no failure on the part of the Company
or, to the knowledge of the Company, any of the Company’s directors or officers, in their
capacities as such, to comply with any applicable provision of the Xxxxxxxx-Xxxxx Act of
2002 and the rules and regulations promulgated in connection therewith (the “Xxxxxxxx-Xxxxx
Act”), including Section 402 related to loans.
(nn) Status under the Securities Act. At the time of filing the Registration Statement
and any post-effective amendment thereto, at the earliest time thereafter that the Company
or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2)
under the
-13-
Securities Act) of the Shares and at the date hereof, the Company was not and is not an
“ineligible issuer,” as defined in Rule 405 under the Securities Act.
(oo) Winding up, Liquidation and Dissolution. The Company has not taken any action,
nor have any legal proceedings been commenced nor, to the knowledge of the Company,
threatened against the Company, for the winding up, liquidation or dissolution of the
Company.
(pp) Aircraft Lease Documents. Each of the lease agreements, lease addenda, side
letters, assignments of warranties, option agreements or similar agreements (not including
non-binding term sheets or letters of intent) to which the Company or any of its
subsidiaries is a party (collectively, the “Aircraft Lease Documents”), is in full force and
effect, except in each case as would not reasonably be expected to have a Material Adverse
Effect; and, to the knowledge of the Company, no event of default (as so defined) has
occurred and is continuing under any Aircraft Lease Document, except for such events of
default as would not reasonably be expected to have a Material Adverse Effect.
(qq) Aircraft Purchase Documents. The Company and/or its subsidiaries have entered
into one or more aircraft purchase agreements (the “Aircraft Purchase Documents”) and
letters of intent for the purchase of aircraft as described in or contemplated by the
Registration Statement, the Pricing Disclosure Package and the Prospectus. The Aircraft
Purchase Documents entered into by the Company or any of its subsidiaries are in full force
and effect and, to the Company’s knowledge, no event of default (as defined in the
applicable Aircraft Purchase Document) has occurred and is continuing under any Aircraft
Purchase Document, except for such events of default as would not reasonably be expected to
have a Material Adverse Effect.
(rr) Aviation Laws. The Company and its subsidiaries are in compliance with all
applicable laws, regulations or other requirements of the U.S. Federal Aviation
Administration, the European Aviation Safety Agency and similar aviation regulatory bodies
(collectively, “Aviation Laws”), and neither the Company nor any of its subsidiaries has
received any written, or to the knowledge of the Company, other notice of a failure to
comply with applicable Aviation Law, except for any failures to comply that would not
reasonably be expected to have a Material Adverse Effect.
(ss) Market Stand-off Agreement. Pursuant to Section 8 of the Registration Rights
Agreement, dated June 4, 2010 between the Company and FBR Capital Markets & Co. (the
“Registration Rights Agreement”), the Company has requested each “Holder” of “Registrable
Shares” (as defined in the Registration Rights Agreement) to not directly or indirectly
sell, offer to sell (including without limitation any short sale), grant any option or
otherwise transfer or dispose of any Registrable Shares or other shares of Common Stock (as
defined in the Registration Rights Agreement) of the Company or any securities convertible
into or exchangeable or exercisable for shares of Common Stock of the Company owned by such
Holder (other than to donees or partners of the Holder who agree to be similarly bound) for
a period (i) in the case of the Company’s officers, directors and employees, in each case to
the extent such person or entity holds shares of Common Stock or securities convertible into
or exchangeable or exercisable for shares of Common Stock, beginning on the effective date
of, and continuing for 180 days following the effective date of, the Registration Statement;
and (ii) in the case of all other Holders, beginning on the effective date of, and
continuing for 60 days following the effective date of the Registration Statement.
(tt) Registration Rights Agreement. The Registration Rights Agreement has been duly
authorized, executed and delivered by the Company and constitutes a valid and legally
-14-
binding agreement of the Company enforceable against the Company in accordance with its
terms, except as enforceability may be limited by applicable bankruptcy, insolvency or
similar laws affecting creditors’ rights generally or by equitable principles relating to
enforceability.
(uu) Unlawfully Directed Shares. The Company has not offered, or caused Barclays
Capital Inc. to offer, Shares to any person pursuant to the Directed Share Program with the
specific intent to unlawfully influence (i) a customer or supplier of the Company to alter
the customer’s or supplier’s level or type of business with the Company or (ii) a trade
journalist or publication to write or publish favorable information about the Company, its
business or its products.
4. Further Agreements of the Company. The Company covenants and agrees with each
Underwriter that:
(a) Required Filings. The Company will file the final Prospectus with the Commission
within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the
Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule
433 under the Securities Act; and will furnish copies of the Prospectus and each Issuer Free
Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York
City prior to 10:00 A.M., New York City time, on the business day next succeeding the date
of this Agreement in such quantities as the Representatives may reasonably request.
(b) Delivery of Copies. The Company will deliver, without charge, (i) to the
Representatives, if so requested in writing, four photocopies of the signed Registration
Statement as originally filed and each amendment thereto, in each case including all
exhibits and consents filed therewith; and (ii) to each Underwriter who so requests (A) a
conformed copy of the Registration Statement as originally filed and each amendment thereto
(without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many
copies of the Prospectus (including all amendments and supplements thereto and each Issuer
Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the
term “Prospectus Delivery Period” means such period of time after the first date of the
public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus
relating to the Shares is required by law to be delivered (or required to be delivered but
for Rule 172 under the Securities Act) in connection with sales of the Shares by any
Underwriter or dealer.
(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before using,
authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and
before filing any amendment or supplement to the Registration Statement or the Prospectus,
the Company will furnish to the Representatives and counsel for the Underwriters a copy of
the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not
use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file
any such proposed amendment or supplement to which the Representatives reasonably object in
a timely fashion.
(d) Notice to the Representatives. The Company will advise the Representatives
promptly, and confirm such advice in writing (which confirmation may be delivered via
email), (i) when the Registration Statement has become effective; (ii) when any amendment to
the Registration Statement has been filed or becomes effective; (iii) when any supplement to
the Prospectus or any Issuer Free Writing Prospectus or any amendment to the Prospectus has
been filed; (iv) of any request by the Commission for any amendment to the Registration
Statement or any amendment or supplement to the Prospectus or the receipt of any comments
from the Commission relating to the Registration Statement or any other request by the
Commission for
-15-
any additional information; (v) of the issuance by the Commission of any order
suspending the effectiveness of the Registration Statement or preventing or suspending the
use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus
or, to the knowledge of the Company, the initiation or threatening of any proceeding for
that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any
event within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing
Disclosure Package or any Issuer Free Writing Prospectus as then amended or supplemented
would include any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances
existing when the Prospectus, the Pricing Disclosure Package or any such Issuer Free Writing
Prospectus is delivered to a purchaser, not misleading; and (vii) of the receipt by the
Company of any notice with respect to any suspension of the qualification of the Shares for
offer and sale in any jurisdiction or, to the knowledge of the Company, the initiation or
threatening of any proceeding for such purpose; and the Company will use its commercially
reasonable efforts to prevent the issuance of any such order suspending the effectiveness of
the Registration Statement, preventing or suspending the use of any Preliminary Prospectus,
any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification
of the Shares and, if any such order is issued, will use its commercially reasonable efforts
to obtain as soon as possible the withdrawal thereof.
(e) Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event
shall occur or condition shall exist as a result of which the Prospectus as then amended or
supplemented would include any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the
circumstances existing when the Prospectus is delivered to a purchaser, not misleading or
(ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company
will promptly notify the Underwriters thereof and forthwith prepare and, subject to
paragraph (c) above, file with the Commission and furnish to the Underwriters and to such
dealers as the Representatives may designate such amendments or supplements to the
Prospectus as may be necessary so that the statements in the Prospectus as so amended or
supplemented will not, in the light of the circumstances existing when the Prospectus is
delivered to a purchaser, be misleading or so that the Prospectus will comply with law and
(2) if at any time prior to the Closing Date (i) any event shall occur or condition shall
exist as a result of which the Pricing Disclosure Package as then amended or supplemented
would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances
existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or
(ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with
law, the Company will promptly notify the Underwriters thereof and forthwith prepare and,
subject to paragraph (c) above, file with the Commission (to the extent required) and
furnish to the Underwriters and to such dealers as the Representatives may designate such
amendments or supplements to the Pricing Disclosure Package as may be necessary so that the
statements in the Pricing Disclosure Package as so amended or supplemented will not, in the
light of the circumstances existing when the Pricing Disclosure Package is delivered to a
purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.
(f) Blue Sky Compliance. The Company will use its reasonable best efforts, in
cooperation with the Representatives, to qualify the Shares for offer and sale under the
securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably
request and will continue such qualifications in effect so long as required for distribution
of the Shares; provided, that the Company shall not be required to (i) qualify as a
foreign corporation or other entity or as a dealer in securities in any such jurisdiction
where it would not otherwise be required to so
-16-
qualify, (ii) file any general consent to service of process in any such jurisdiction
or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so
subject.
(g) Earning Statement. The Company will make generally available to its stockholders
and the Representatives as soon as practicable an earning statement that satisfies the
provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated
thereunder covering a period of at least twelve months beginning with the first fiscal
quarter of the Company occurring after the “effective date” (as defined in Rule 158) of the
Registration Statement; provided, however, that (i) such requirement with respect to
the Company’s stockholders shall be deemed to be met by the Company’s compliance with its
reporting requirements pursuant to the Exchange Act if such compliance satisfies the
conditions of Rule 158, and (ii) such requirement with respect to the Representatives shall
be deemed to be met by the Company if the related reports are available on the Commission’s
Electronic Data Gathering Analysis and Retrieval system.
(h) Clear Market. For a period of 180 days after the date of the Prospectus, the
Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, directly or indirectly, or, except in the
case of a registration statement on Form S-8 with respect to employee benefits plans
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and any registration statement required to be filed in order to meet the Company’s
obligations under the Registration Rights Agreement as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus (the filing of which will occur
on April 29, 2011), file with the Commission a registration statement under the Securities
Act relating to, any shares of Stock or any securities convertible into or exercisable or
exchangeable for Stock, or publicly disclose the intention to make any offer, sale, pledge,
disposition or filing, or (ii) enter into any swap or other agreement that transfers, in
whole or in part, any of the economic consequences of ownership of the Stock or any such
other securities, whether any such transaction described in clause (i) or (ii) above is to
be settled by delivery of Stock or such other securities, in cash or otherwise, without the
prior written consent of X. X. Xxxxxx Securities LLC and Credit Suisse Securities (USA) LLC,
other than (A) the Shares to be sold hereunder, (B) any shares of Stock issued upon exercise
of outstanding warrants described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, (C) any stock options, restricted stock units or other
equity-based awards, and any shares of Stock underlying or subject to such compensatory
awards, granted pursuant to employee benefit plans, equity incentive plans or other employee
compensation plans disclosed in the Registration Statement, the Pricing Disclosure Package
and the Prospectus, provided, that such awards and the shares underlying or subject
to such awards shall not vest during the 180-day period referred to above, except in
connection with terminations of service, death, disability, or a change in control in
accordance with the terms and conditions of the relevant plan and award or other agreement,
(D) any shares of Stock of the Company issued upon the exercise of options or the vesting of
restricted stock units outstanding on the date hereof and described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (E) any securities issued in
connection with the acquisition by the Company of the securities, business, property or
other assets of another person or entity, or pursuant to any employee benefit plan assumed
by the Company in connection with any such acquisition, or (F) any securities issued in
connection with joint ventures, commercial relationships or other strategic transactions,
provided, that prior to any issuance in the case of clause (E) or (F), the Company
shall cause each such recipient of such securities to execute and deliver to the
Representatives a Lock-Up Agreement substantially in the form of Exhibit A, and
provided, further, that any issuances in the case of clause (E) or (F) shall not, in
the aggregate, exceed 10% of the shares of capital stock of the Company outstanding
-17-
immediately following the later of the Closing Date and the last Additional Closing
Date. Notwithstanding the foregoing, if (1) during the last 17 days of the 180-day
restricted period, the Company issues an earnings release or material news or a material
event relating to the Company occurs; or (2) prior to the expiration of the 180-day
restricted period, the Company announces that it will release earnings results during the
16-day period beginning on the last day of the 180-day period, the restrictions imposed by
this Agreement shall continue to apply until the expiration of the 18-day period beginning
on the issuance of the earnings release or the occurrence of the material news or material
event.
(i) Use of Proceeds. The Company will apply the net proceeds from the sale of the
Shares as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus under the heading “Use of proceeds”.
(j) No Stabilization. The Company will not take, directly or indirectly, any action
designed to or that would reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Stock (it being understood that the Company makes no
statement as to the activities of the Underwriters in connection with the offering).
(k) Exchange Listing. The Company will use its reasonable best efforts to list,
subject to official notice of issuance, the Shares on the Exchange.
(l) Reports. During the period commencing on the Closing Date and ending on the later
of (i) the date that is two years following the Closing Date and (ii) the end of the
Prospectus Delivery Period, the Company will make available to the Representatives, promptly
after they are available, copies of all reports or other communications (financial or other)
furnished by the Company to holders of the Shares, and copies of any reports and financial
statements furnished to or filed by the Company with the Commission or any national
securities exchange or automatic quotation system; provided, that the Company will
be deemed to have furnished such reports and financial statements to the Representatives to
the extent they are filed on the Commission’s Electronic Data Gathering, Analysis, and
Retrieval system.
(m) Record Retention. The Company will, pursuant to reasonable procedures developed in
good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the
Commission for three years in accordance with Rule 433 under the Securities Act.
(n) Filings. The Company will file with the Commission such reports as may be required
by Rule 463 under the Securities Act.
(o) Restricted Directed Shares. The Company will, in connection with the Directed
Share Program, use commercially reasonable efforts to ensure that the Directed Shares will
be restricted from sale, transfer, assignment, pledge or hypothecation to at least the same
extent that sales and dispositions of Stock by the Company are restricted pursuant to
Section 4(h), and Barclays Capital Inc. will notify the Company as to which Directed Share
Participants will need to be so restricted.
(p) Market Stand-off Agreement. The Company shall not amend or waive any restriction
relating to its request to Holders (as defined in the Registration Rights Agreement)
pursuant to Section 8 of the Registration Rights Agreement and described in Section 3(ss) of
this Agreement, except with the prior written consent of the Representatives.
-18-
5. Certain Agreements of the Underwriters. Each Underwriter hereby represents and
agrees that:
(a) It has not used, authorized use of, referred to or participated in the planning for
use of, and will not use, authorize use of, refer to or participate in the planning for use
of, any “free writing prospectus”, as defined in Rule 405 under the Securities Act, required
to be filed with the Commission (which term includes use of any written information
furnished to the Commission by the Company and not incorporated by reference into the
Registration Statement and any press release issued by the Company) other than (i) a free
writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2) under
the Securities Act) that was not included (including through incorporation by reference) in
the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any
Issuer Free Writing Prospectus listed on Annex E or prepared pursuant to Section 3(c) or
Section 4(c) above (including any electronic road show approved by the Company), or (iii)
any free writing prospectus prepared by such underwriter and approved by the Company in
advance in writing.
(b) It has not and will not, without the prior written consent of the Company, use any
free writing prospectus that contains the final terms of the Shares unless such terms have
previously been included in a free writing prospectus filed with the Commission;
provided, that the Underwriters may use a term sheet substantially in the form of
Annex F hereto without the consent of the Company; provided, further, that any
Underwriter using such term sheet shall notify the Company, and provide a copy of such term
sheet to the Company, prior to, or substantially concurrently with, the first use of such
term sheet.
(c) It is not subject to any pending proceeding under Section 8A of the Securities Act
with respect to the offering (and will promptly notify the Company if any such proceeding
against it is initiated during the Prospectus Delivery Period).
6. Conditions of Underwriters’ Obligations. The obligation of each Underwriter to
purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing
Date, as the case may be, as provided herein is subject to the performance by the Company of its
covenants and other obligations hereunder and to the following additional conditions:
(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of
the Registration Statement shall be in effect, and no proceeding for such purpose or
pursuant to Section 8A under the Securities Act shall be pending before or, to the knowledge
of the Company, threatened by the Commission; the Prospectus and each Issuer Free Writing
Prospectus shall have been timely filed with the Commission under the Securities Act (in the
case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the
Securities Act) and in accordance with Section 4(a) hereof; and all requests by the
Commission for additional information shall have been complied with to the reasonable
satisfaction of the Representatives.
(b) Representations and Warranties. The representations and warranties of the Company
contained herein shall be true and correct on the date hereof and on and as of the Closing
Date or the Additional Closing Date, as the case may be; and the statements of the Company
and its officers made in any certificates delivered pursuant to this Agreement shall be true
and correct on and as of the Closing Date or the Additional Closing Date, as the case may
be.
(c) No Downgrade. Subsequent to the earlier of (A) the Applicable Time and (B) the
execution and delivery of this Agreement, if there are any debt securities or preferred
stock of, or guaranteed by, the Company or any of its subsidiaries that are rated by a
“nationally
-19-
recognized statistical rating organization,” as such term is defined in the Exchange
Act, (i) no downgrading shall have occurred in the rating accorded any such debt securities
or preferred stock and (ii) no such organization shall have publicly announced that it has
under surveillance or review, or has changed its outlook with respect to, its rating of any
such debt securities or preferred stock (other than an announcement with positive
implications of a possible upgrading).
(d) No Material Adverse Change. No event or condition of a type described in Section
3(f) hereof shall have occurred or shall exist, which event or condition is not described in
the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the
Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the
offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date,
as the case may be, on the terms and in the manner contemplated by this Agreement, the
Pricing Disclosure Package and the Prospectus.
(e) Officer’s Certificate. The Representatives shall have received on and as of the
Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief
financial officer or chief accounting officer of the Company and one additional senior
executive officer of the Company who is reasonably satisfactory to the Representatives (i)
confirming that such officers have reviewed the Registration Statement, the Pricing
Disclosure Package and the Prospectus and, to the knowledge of such officers, the
representations of the Company set forth in Sections 3(b) and 3(d) hereof are true and
correct, (ii) confirming that the other representations and warranties of the Company in
this Agreement are true and correct and that the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior
to the Closing Date or the Additional Closing Date, as the case may be, and (iii) to the
effect set forth in paragraphs (a), (c) and (d) above.
(f) Comfort Letters. On the date of this Agreement and on the Closing Date or the
Additional Closing Date, as the case may be, KPMG LLP shall have furnished to the
Representatives, at the request of the Company, letters, dated the respective dates of
delivery thereof and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representatives, containing statements and information of the type
customarily included in accountants’ “comfort letters” to underwriters with respect to the
financial statements and certain financial information contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus; provided, that the
letter delivered on the Closing Date or the Additional Closing Date, as the case may be,
shall use a “cut-off” date no more than three business days prior to such Closing Date or
such Additional Closing Date, as the case may be.
(g) Opinion and 10b-5 Statement of Counsel for the Company. Xxxxxx, Xxxxxx & Xxxxx
LLP, counsel for the Company, shall have furnished to the Representatives, at the request of
the Company, their written opinion and 10b-5 statement, dated the Closing Date or the
Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representatives, to the effect set forth in Annex A
and Annex B hereto.
(h) Opinion of General Counsel for the Company. Xxxxx X. Xxxx, Executive Vice
President, General Counsel and Secretary for the Company, shall have furnished to the
Representatives, at the request of the Company, a written opinion and 10b-5 statement, dated
the Closing Date or the Additional Closing Date, as the case may be, and addressed to the
Underwriters, in form and substance reasonably satisfactory to the Representatives, to the
effect set forth in Annex C and Annex D hereto.
-20-
(i) Opinion and 10b-5 Statement of Counsel for the Underwriters. The Representatives
shall have received on and as of the Closing Date or the Additional Closing Date, as the
case may be, an opinion and 10b-5 statement of Xxxxx Xxxx & Xxxxxxxx LLP, counsel for the
Underwriters, with respect to such matters as the Representatives may reasonably request,
and such counsel shall have received such documents and information as they may reasonably
request to enable them to pass upon such matters.
(j) No Legal Impediment to Issuance. No action shall have been taken and no statute,
rule, regulation or order shall have been enacted, adopted or issued by any federal, state
or foreign governmental or regulatory authority that would, as of the Closing Date or the
Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and
no injunction or order of any federal, state or foreign court shall have been issued that
would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent
the issuance or sale of the Shares.
(k) Good Standing. The Representatives shall have received on and as of the Closing
Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good
standing of the Company and its Significant Subsidiaries in their respective jurisdictions
of organization and their good standing as foreign entities in such other jurisdictions as
the Representatives may reasonably request, in each case in writing or any standard form of
telecommunication from the appropriate governmental authorities of such jurisdictions.
(l) Exchange Listing. The Shares to be delivered on the Closing Date or Additional
Closing Date, as the case may be, shall have been approved for listing on the Exchange,
subject to official notice of issuance.
(m) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of
Exhibit A hereto, between the Representatives and (i) the officers and directors of the
Company and (ii) stockholders of the Company affiliated with such directors, relating to
sales and certain other dispositions of shares of Stock or certain other securities,
delivered to you on or before the date hereof, shall be in full force and effect on the
Closing Date or Additional Closing Date, as the case may be.
(n) Additional Documents. On or prior to the Closing Date or the Additional Closing
Date, as the case may be, the Company shall have furnished to the Representatives such
further certificates and documents as the Representatives may reasonably request.
All opinions, letters, certificates and evidence mentioned above or elsewhere in this
Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriters.
7. Indemnification and Contribution.
(a) Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless
each Underwriter, its partners, members, employees, agents, affiliates, directors and officers and
each person, if any, who controls such Underwriter within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims,
damages and liabilities (including, without limitation, reasonable legal fees and other reasonable
expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such
fees and expenses are incurred), joint or several, that arise out of, or are based upon, (i) any
untrue statement or alleged untrue statement of a material fact contained in the Registration
Statement or caused by any omission or alleged omission to
-21-
state therein a material fact required to be stated therein or necessary in order to make the
statements therein not misleading, or (ii) any untrue statement or alleged untrue statement of a
material fact contained in the Prospectus (or any amendment or supplement thereto), any Issuer Free
Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d)
under the Securities Act or any Pricing Disclosure Package (including any Pricing Disclosure
Package that has subsequently been amended), or caused by any omission or alleged omission to state
therein a material fact necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading, in each case except insofar as such
losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or
omission or alleged untrue statement or omission made in reliance upon and in conformity with any
information relating to any Underwriter furnished to the Company in writing by such Underwriter
through the Representatives expressly for use therein, it being understood and agreed that the only
such information furnished by any Underwriter consists of the information described as such in
subsection (b) below.
(b) Indemnification of the Company. Each Underwriter agrees, severally and not jointly, to
indemnify and hold harmless the Company, its affiliates, its directors, its officers who signed the
Registration Statement and each person, if any, who controls the Company within the meaning of
Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the
indemnity set forth in paragraph (a) above, but only with respect to any losses, claims, damages or
liabilities (including, without limitation, reasonable legal fees and other reasonable expenses
incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and
expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or
alleged untrue statement or omission made in reliance upon and in conformity with any information
relating to such Underwriter furnished to the Company in writing by such Underwriter through the
Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment
or supplement thereto), any Issuer Free Writing Prospectus or any Pricing Disclosure Package, it
being understood and agreed upon that the only such information furnished by any Underwriter
consists of the following information in the Registration Statement, the Preliminary Prospectus,
and the Prospectus, as applicable, furnished on behalf of each Underwriter: (i) the statements
regarding the delivery of the Shares by the Underwriters and the names of the Underwriters set
forth on the cover page, and (ii) the concession and reallowance figures appearing in the third
paragraph, the information relating to the availability of prospectuses and the allocation of
shares in the seventh paragraph, and the information relating to stabilizing transactions contained
in the thirteenth, fourteenth and fifteenth paragraphs, in each case under the caption
“Underwriting”.
(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or
regulatory investigation), claim or demand shall be brought or asserted against any person in
respect of which indemnification may be sought pursuant to either paragraph (a) or (b) above, such
person (the “Indemnified Person”) shall promptly notify the person against whom such
indemnification may be sought (the “Indemnifying Person”) in writing; provided, that the
failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under paragraph (a) or (b) above except to the extent that it has been materially prejudiced
(through the forfeiture of substantive rights or defenses) by such failure; and provided,
further, that the failure to notify the Indemnifying Person shall not relieve it from any
liability that it may have to an Indemnified Person otherwise than under paragraph (a) or (b)
above. If any such proceeding shall be brought or asserted against an Indemnified Person and it
shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel
reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the
Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person in
such proceeding and shall pay the reasonable fees and expenses of such counsel related to such
proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to
retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person
shall have mutually agreed to the contrary; (ii) the
-22-
Indemnifying Person has failed within a reasonable time to retain counsel reasonably
satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably
concluded based on the advice of counsel that there may be legal defenses available to it that
conflict with those available to the Indemnifying Person; or (iv) the named parties in any such
proceeding (including any impleaded parties) include both the Indemnifying Person and the
Indemnified Person and representation of both parties by the same counsel would be inappropriate
due to actual or potential conflict between them. It is understood and agreed that the
Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to
any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid
or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates,
directors and officers and any control persons of such Underwriter shall be designated in writing
by X. X. Xxxxxx Securities LLC and Credit Suisse Securities (USA) LLC and any such separate firm
for the Company, its affiliates, its directors, its officers who signed the Registration Statement
and any control persons of the Company shall be designated in writing by the Company. The
Indemnifying Person shall not be liable for any settlement of any proceeding effected without its
written consent, but if settled with such consent or if there be a final judgment for the
plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any
loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing
sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person
reimburse the Indemnified Person for fees and expenses of counsel as contemplated by this
paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected
without its written consent if (i) such settlement is entered into more than 30 days after receipt
by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have
reimbursed the Indemnified Person in accordance with such request prior to the date of such
settlement; provided, however, that the Indemnifying Person shall not be liable for such
settlement if the delay in such reimbursement is due to (A) a dispute, with reasonable basis,
regarding the amount of fees and expenses for which such reimbursement is sought or (B) a
good-faith dispute based on the advice of counsel regarding the Indemnified Person’s entitlement to
reimbursement of such fees and expenses. No Indemnifying Person shall, without the written consent
of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect
of which any Indemnified Person is or could have been a party and indemnification could have been
sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional
release of such Indemnified Person, in form and substance reasonably satisfactory to such
Indemnified Person, from all liability on claims that are the subject matter of such proceeding and
(y) does not include any statement as to or any admission of fault, culpability or a failure to act
by or on behalf of any Indemnified Person.
(d) Contribution. If the indemnification provided for in paragraphs (a) and (b) above is
unavailable as a matter of law to an Indemnified Person in respect of any losses, claims, damages
or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of
indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by
such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such
proportion as is appropriate to reflect the relative benefits received by the Company, on the one
hand, and the Underwriters, on the other, from the offering of the Shares or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) but also the relative fault of the
Company, on the one hand, and the Underwriters, on the other, in connection with the statements or
omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company, on the one hand,
and the Underwriters, on the other, shall be deemed to be in the same respective proportions as the
net proceeds (before deducting expenses but after deducting underwriting discounts and commissions)
received by the Company from the sale of the Shares and the total underwriting discounts and
commissions received by the Underwriters in connection therewith, in each case as set forth in the
table on the cover of the Prospectus, bear to the aggregate offering price of
-23-
the Shares. The relative fault of the Company, on the one hand, and the Underwriters, on the
other, shall be determined by reference to, among other things, whether the untrue or alleged
untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Underwriters, and the parties’ relative
intent, knowledge, access to information and opportunity to correct or prevent such statement or
omission.
(e) Limitation on Liability. The Company and the Underwriters agree that it would not be just
and equitable if contribution pursuant to this Section 7 were determined by pro
rata allocation (even if the Underwriters were treated as one entity for such purpose) or
by any other method of allocation that does not take account of the equitable considerations
referred to in paragraph (d) above. The amount paid or payable by an Indemnified Person as a
result of the losses, claims, damages and liabilities referred to in paragraph (d) above shall be
deemed to include, subject to the limitations set forth above, any reasonable legal or other
reasonable expenses incurred by such Indemnified Person in connection with any such action or
claim. Notwithstanding the provisions of this Section 7, in no event shall an Underwriter be
required to contribute any amount in excess of the amount by which the total underwriting discounts
and commissions received by such Underwriter with respect to the offering of the Shares exceeds the
amount of any damages that such Underwriter has otherwise been required to pay by reason of such
untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters’ obligations to contribute pursuant to this Section 7 are several in proportion to
their respective purchase obligations hereunder and not joint.
(f) Directed Share Program Indemnification. The Company shall indemnify and hold harmless
Barclays Capital Inc. (including its directors, officers and employees) and each person, if any,
who controls Barclays Capital Inc. within the meaning of Section 15 of the Securities Act
(“Barclays Capital Entities”), from and against any loss, claim, damage or liability or any action
in respect thereof to which any of the Barclays Capital Entities may become subject, under the
Securities Act or otherwise, insofar as such loss, claim, damage, liability or action (i) arises
out of, or is based upon, any untrue statement or alleged untrue statement of a material fact
contained in any material prepared by or with the approval of the Company for distribution to
Directed Share Participants in connection with the Directed Share Program or any omission or
alleged omission to state therein a material fact required to be stated therein or necessary to
make the statements therein not misleading, (ii) arises out of, or is based upon, the failure of
the Directed Share Participant to pay for and accept delivery of Directed Shares that the Directed
Share Participant agreed to purchase or (iii) is otherwise related to the Directed Share Program;
provided, that the Company shall not be liable under this clause (iii) for any loss, claim,
damage, liability or action that is determined in a final judgment by a court of competent
jurisdiction to have resulted from the gross negligence or willful misconduct of the Barclays
Capital Entities. The Company shall reimburse the Barclays Capital Entities promptly upon demand
for any legal or other expenses reasonably incurred by them in connection with investigating or
defending or preparing to defend against any such loss, claim, damage, liability or action as such
expenses are incurred.
(g) Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and
shall not limit any rights or remedies which may otherwise be available to any Indemnified Person
at law or in equity.
8. Effectiveness of Agreement. This Agreement shall become effective upon the
execution and delivery hereof by the parties hereto.
9. Termination. This Agreement may be terminated in the absolute discretion of the
Representatives, by notice to the Company, if after the execution and delivery of this Agreement
and prior
-24-
to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date
(i) trading generally shall have been suspended or materially limited on or by either the Exchange
or the Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company
shall have been suspended on any exchange or in any over-the-counter market; (iii) a general
moratorium on commercial banking activities shall have been declared by federal or New York State
authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any
change in financial markets or any calamity or crisis, either within or outside the United States,
that, in the judgment of the Representatives, is material and adverse and makes it impracticable or
inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the
Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this
Agreement, the Pricing Disclosure Package and the Prospectus.
10. Defaulting Underwriter.
(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any
Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase
hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the
purchase of such Shares by other persons satisfactory to the Company on the terms contained in this
Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting
Underwriters do not arrange for the purchase of such Shares, then the Company shall be entitled to
a further period of 36 hours within which to procure other persons satisfactory to the
non-defaulting Underwriters to purchase such Shares on such terms. If other persons become
obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting
Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the
case may be, for up to five full business days in order to effect any changes that in the opinion
of counsel for the Company or counsel for the Underwriters may be necessary in the Registration
Statement and the Prospectus or in any other document or arrangement, and the Company agrees to
promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that
effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all
purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule
1 hereto that, pursuant to this Section 10, purchases Shares that a defaulting Underwriter agreed
but failed to purchase.
(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in
paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate
number of Shares to be purchased on such date, then the Company shall have the right to require
each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to
purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of
Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting
Underwriter or Underwriters for which such arrangements have not been made.
(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting
Underwriter or Underwriters by the non-defaulting Underwriters and the Company as provided in
paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of
Shares to be purchased on such date, or if the Company shall not exercise the right described in
paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the
obligation of the Underwriters to purchase Shares on the Additional Closing Date shall terminate
without liability on the part of the non-defaulting Underwriters or the Company, except that the
Company and the Underwriters
-25-
will continue to be liable for the payment of expenses as set forth in Section 11 hereof and
except that the provisions of Section 7 hereof shall not terminate and shall remain in effect.
(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may
have to the Company or any non-defaulting Underwriter for damages caused by its default.
11. Payment of Expenses.
(a) Whether or not the transactions contemplated by this Agreement are consummated or this
Agreement is terminated, the Company will pay or cause to be paid all costs and expenses incident
to the performance of its obligations hereunder, including without limitation, (i) the costs
incident to the authorization, issuance, sale, preparation and delivery of the Shares and any taxes
payable in that connection; (ii) the costs incident to the preparation, printing and filing under
the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free
Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits,
amendments and supplements thereto) and the distribution thereof; (iii) the fees and expenses of
the Company’s counsel and independent accountants; (iv) the fees and expenses incurred in
connection with the registration or qualification of the Shares under the state or foreign
securities or blue sky or world sky laws of, and/or in connection with determining the conditions
under which such registration or qualification need not be obtained in order to offer and sell
Shares in, such jurisdictions as the Representatives may designate (subject to the limitations set
forth in Section 4(f)) and the preparation, printing and distribution of a Canadian wrapper, Blue
Sky Memorandum and/or World Sky Memorandum (including in each case the related reasonable fees and
expenses of counsel for the Underwriters, including local counsel in each such foreign
jurisdiction, provided, however, that the fees and expenses of counsel incurred in
connection with the Canadian Wrapper and the Blue Sky Memorandum and/or World Sky Memorandum shall
not exceed $100,000 in the aggregate, and provided, further, that the Company shall
not pay for any such Canadian Wrapper, Blue Sky and World Sky fees and expenses if the transactions
contemplated by this Agreement are not consummated, notwithstanding anything to the contrary
herein); (v) the cost of preparing stock certificates; (vi) the costs and charges of any transfer
agent and any registrar; (vii) all expenses and application fees incurred in connection with any
filing with, and clearance of the offering by, FINRA (including the reasonable related fees and
expenses of counsel for the Underwriters); (viii) all expenses incurred by the Company in
connection with any “road show” presentation to potential investors (provided, however,
that the cost of any aircraft chartered or used for the road show shall be borne 50% by the
Underwriters); (ix) the offer and sale of shares of the Shares by the Underwriters in connection
with the Directed Share Program, including the reasonable fees and disbursements of counsel to the
Underwriters related thereto, the costs and expenses of preparation, printing and distribution of
the Directed Share Program material and all stamp duties or other taxes incurred by the
Underwriters in connection with the Directed Share Program and (x) all expenses and application
fees related to the listing of the Shares on the Exchange. It is understood, however, that except
as provided in this Agreement, the Underwriters will pay all costs and expenses incurred by them,
including, without limitation, all expenses incurred by the Underwriters in connection with any
“road show” presentation to potential investors (as well as 50% of the cost of any aircraft
chartered or used for the road show), fees and disbursements of their counsel, stock transfer taxes
payable on resale of any Shares by them, and any advertising expenses connected with any offers
they may make. For the avoidance of doubt, it is understood that the Company shall not pay or
reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations
to purchase the Shares.
(b) If (i) this Agreement is terminated pursuant to Section 9, (ii) the Company for any reason
(other than pursuant to Section 10) fails to tender the Shares for delivery to the Underwriters or
(iii) the Underwriters decline to purchase the Shares for any reason permitted under this
Agreement, the Company agrees to reimburse the Underwriters for all documented out-of-pocket costs
and expenses (including the
-26-
reasonable fees and expenses of their counsel) reasonably incurred by the Underwriters in
connection with this Agreement and the offering contemplated hereby; provided, however,
that for purposes of this Section 10(b), the Company shall in no event be liable to any of the
Underwriters for any other amounts, including, without limitation, damages on account of loss of
anticipated profits from the sale of the Shares. Notwithstanding anything herein to the contrary,
in no event shall the Company be responsible, or obligated to reimburse the Underwriters, for any
costs or expenses incurred by the Underwriters in connection with any road show. For the avoidance
of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses
incurred by any Underwriter that defaults on its obligations to purchase the Shares.
12. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the
benefit of and be binding upon the parties hereto and their respective successors and the officers
and directors and any controlling persons referred to in Section 7 hereof. Nothing in this
Agreement is intended or shall be construed to give any other person any legal or equitable right,
remedy or claim under or in respect of this Agreement or any provision contained herein. No
purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such
purchase.
13. Survival. The respective indemnities, rights of contribution, representations,
warranties and agreements of the Company and the Underwriters contained in this Agreement or made
by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate
delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain
in full force and effect, regardless of any termination of this Agreement or any investigation made
by or on behalf of the Company or the Underwriters.
14. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise
expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities
Act; (b) the term “business day” means any day other than a day on which banks are permitted or
required to be closed in New York City; and (c) the term “subsidiary” has the meaning set forth in
Rule 405 under the Securities Act.
15. Miscellaneous.
(a) Authority of X. X. Xxxxxx Securities LLC and Credit Suisse Securities (USA) LLC. Any
action by the Underwriters hereunder may be taken by X. X. Xxxxxx Securities LLC and Credit Suisse
Securities (USA) LLC on behalf of the Underwriters, and any such action taken by X. X. Xxxxxx
Securities LLC or Credit Suisse Securities (USA) LLC shall be binding upon the Underwriters, and
the parties hereto shall be entitled to act and rely upon any statement, request, notice or
agreement made or given by the Representatives on behalf of the Underwriters.
(b) Notices. All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if mailed or transmitted and confirmed by any standard form of
telecommunication. Notices to the Underwriters shall be given to the Representatives c/o X. X.
Xxxxxx Securities LLC, 000 Xxxxxxx Xxxxxx, Xxx Xxxx, Xxx Xxxx 00000 (fax: (000) 000-0000);
Attention Equity Syndicate Desk; and Credit Suisse Securities (USA) LLC, Eleven Madison Avenue,
New York, N.Y. 10010-3629, Attention: LCD-IBD. Notices to the Company shall be given to it at
0000 Xxxxxx xx xxx Xxxxx, Xxxxx 0000X, Xxx Xxxxxxx, Xxxxxxxxxx 00000, (fax: (000) 000-0000);
Attention: Xxxx X. Xxxxxxx, President and Chief Operating Officer.
(c) Governing Law. This Agreement and any claim, controversy or dispute arising under or
related to this Agreement shall be governed by and construed in accordance with the laws of the
State of New York applicable to agreements made and to be performed in such state.
-27-
(d) Severability. The invalidity or unenforceability of any Section, paragraph, or provision
of this Agreement shall not affect the validity or enforceability of any other Section, paragraph,
or provision hereof; provided, that no such severability shall be effective if it
materially changes the economic benefit of this Agreement to any party hereto.
(e) Counterparts. This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an
original and all of which together shall constitute one and the same instrument.
(f) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any
consent or approval to any departure therefrom, shall in any event be effective unless the same
shall be in writing and signed by the parties hereto.
(g) Headings. The headings herein are included for convenience of reference only and are not
intended to be part of, or to affect the meaning or interpretation of, this Agreement.
[Remainder of page intentionally left blank]
-28-
If the foregoing is in accordance with your understanding, please indicate your acceptance of
this Agreement by signing in the space provided below.
Very truly yours, AIR LEASE CORPORATION |
||||
By: | ||||
Name: | ||||
Title: |
Accepted:
, 2011
X. X. XXXXXX SECURITIES LLC
By: | |
CREDIT SUISSE SECURITIES (USA) LLC
By: | Title: |
For themselves and on behalf of the
several Underwriters listed
in Schedule 1 hereto.
several Underwriters listed
in Schedule 1 hereto.
Accepted: , 2011
BARCLAYS CAPITAL INC.
By: | |
As Directed Share Program agent
Schedule 1
Underwriter | Number of Shares | ||||
X. X. Xxxxxx Securities LLC |
|||||
Credit Suisse Securities (USA) LLC |
|||||
Barclays Capital Inc. |
|||||
FBR Capital Markets & Co. |
|||||
RBC Capital Markets Corporation |
|||||
Xxxxx Fargo Securities, LLC |
|||||
Macquarie Capital (USA) Inc. |
|||||
Scotia Capital (USA) Inc. |
|||||
SG Americas Securities, LLC |
|||||
Total | |||||
Schedule 2
Significant Subsidiaries
Annex A
Form of Opinion of Counsel for the Company
Annex B
Form of 10b-5 Statement of Counsel for the Company
Annex C
Form of Opinion of General Counsel for the Company
Annex D
Form of 10b-5 Statement of General Counsel for the Company
Annex E
a. Pricing Disclosure Package
b. Pricing Information Provided Orally by Underwriters
Exhibit A
FORM OF LOCK-UP AGREEMENT
, 2011
X. X. Xxxxxx Securities LLC
Credit Suisse Securities (USA) LLC
As Representatives of the
several Underwriters listed
in Schedule 1 to the Underwriting
Agreement referred to below
c/o X. X. Xxxxxx Securities LLC
000 Xxxxxxx Xxxxxx
Xxx Xxxx, XX 00000
Credit Suisse Securities (USA) LLC
As Representatives of the
several Underwriters listed
in Schedule 1 to the Underwriting
Agreement referred to below
c/o X. X. Xxxxxx Securities LLC
000 Xxxxxxx Xxxxxx
Xxx Xxxx, XX 00000
Re: Air
Lease Corporation --- Public Offering
Ladies and Gentlemen:
The undersigned understands that Air Lease Corporation, a Delaware corporation (the
“Company”), and X. X. Xxxxxx Securities LLC and Credit Suisse Securities (USA) LLC, as representatives (the “Representatives”) of the several Underwriters, propose to
enter into an underwriting agreement (the “Underwriting Agreement”), providing for the initial
public offering (the “Public Offering”) by the several Underwriters to be named in Schedule 1 to
the Underwriting Agreement (the “Underwriters”), of Class A Common Stock, par value $0.01 per
share, of the Company (the “Securities”).
In consideration of the Underwriters’ agreement to purchase and make the Public Offering of
the Securities, and for other good and valuable consideration receipt of which is hereby
acknowledged, the undersigned hereby agrees that, without the prior written consent of X. X. Xxxxxx
Securities LLC and Credit Suisse Securities (USA) LLC on behalf of the Underwriters, the
undersigned will not, during the period commencing on the date of this Agreement and ending on the
date that is 180 days after the date of the final prospectus relating to the Public Offering (the
“Prospectus”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any shares of Class A Common Stock, par
value $0.01 per share, or any shares of Class B Non-Voting Common Stock, par value $0.01 per share,
of the Company (together, the “Common Stock”) or any securities convertible into or exercisable or
exchangeable for Common Stock (including without limitation, Common Stock or such other securities
which may be deemed to be beneficially owned by the undersigned in accordance with the rules and
regulations of the Securities and Exchange Commission and securities which may be issued upon
exercise of a stock option or warrant), or publicly disclose the intention to make any such offer,
sale, pledge or disposition, (2) enter into any swap or other agreement that transfers, in whole or
in part, any of
the economic consequences of ownership of shares of Common Stock or such other securities,
whether any such transaction described in clause (1) or (2) above is to be settled by delivery of
Common Stock or such other securities, in cash or otherwise or (3) make any demand for or exercise
any right with respect to the registration of any shares of Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock, in each case other than transfers
of shares of any class of the Common Stock of the Company (A) as a bona fide gift or gifts, (B) to
any trust for the direct or indirect benefit of the undersigned and/or any family member of the
undersigned, (C) by will or intestate succession, or (D) in connection with distributions to
partners, members, or stockholders of the undersigned; provided, in each of (A) through (D)
above: (i) that such transfer shall not involve a disposition for value; (ii) that the donee,
transferee, trustee, or distributee, as applicable, shall execute and deliver to the Company and
the Representatives a lock-up letter in the form of this Letter Agreement; and (iii) that no filing
by any party (donor, donee, transferor, transferee, distributor or distributee) under the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other public announcement
shall be required or shall be made voluntarily in connection with such transfer or distribution
(other than a filing on a Form 5 or a Schedule 13G or Schedule 13G/A made after the expiration of
the 180-day restricted period referred to above). Notwithstanding the foregoing, if (1) during the
last 17 days of the 180-day restricted period, the Company issues an earnings release or material
news or a material event relating to the Company occurs; or (2) prior to the expiration of the
180-day restricted period, the Company announces that it will release earnings results during the
16-day period beginning on the last day of the 180-day period, the restrictions imposed by this
Letter Agreement shall continue to apply until the expiration of the 18-day period beginning on the
issuance of the earnings release or the occurrence of the material news or material event, unless
X. X. Xxxxxx Securities LLC and Credit Suisse Securities (USA) LLC shall waive such extension in
writing.
Nothing contained in this Letter Agreement shall prohibit the undersigned from, or restrict
the ability of the undersigned to, purchase shares of the Company’s Class A Common Stock in the
open market or sell such securities purchased in the open market following the consummation of the
Public Offering. For the avoidance of doubt, nothing contained in this Letter Agreement shall
prohibit the undersigned from, or restrict the ability of the undersigned to, exercise any options,
warrants or other convertible securities, receive shares of Common Stock of the Company upon the
vesting of any restricted stock units, or otherwise receive shares of Common Stock of the Company
pursuant to awards granted under any benefit plan of the Company; provided, that any such
Common Stock which may be received will also be subject to this Letter Agreement.
In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the
registration or transfer of the securities described herein, are hereby authorized to decline to
make any transfer of securities if such transfer would constitute a violation or breach of this
Letter Agreement.
The undersigned hereby represents and warrants that the undersigned has full power and
authority to enter into this Letter Agreement. All authority herein conferred or agreed to be
conferred and any obligations of the undersigned shall be binding upon the successors, assigns,
heirs or personal representatives of the undersigned.
This Letter Agreement shall be of no force or effect, and the undersigned shall be released
from all obligations under this Letter Agreement upon the earliest to occur of the following: (i)
if the Company notifies the Representatives in writing before the Underwriting Agreement becomes
effective that it does not intend to proceed with the Public Offering by the Underwriters, (ii) if
the Underwriting Agreement does not become effective by December 31, 2011, or (iii) if the
Underwriting Agreement (other than the provisions thereof which survive termination) shall
terminate or be terminated prior to payment for and delivery of the Securities to be sold
thereunder. The undersigned understands that the Company and the Underwriters are entering into the Underwriting Agreement and proceeding with the Public
Offering in reliance upon this Letter Agreement.
This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New
York, without regard to the conflict of laws principles thereof.
Very truly yours, |
||||
By: | ___________________________________ | |||
Name: | ||||
Title: | ||||